Nanjing, China., Nov 23, 2019-IASO Biotherapeutics(IASO Bio), a clinical stage biotechnology company advancing the development of innovative therapies for cancer, today announced that IASO Bio will give an oral presentation with title 'Efficacy and Safety of Fully Human BCMA Targeting CAR T Cell Therapy in Relapsed Refractory Multiple Myeloma' (publication # 582) at American Society of Hematology, 61st ASH Annual Meeting & Exposition in Orlando, FL. on Dec. 7-10.
Nanjing, China., Sept 1, 2019-IASO Biotherapeutics(IASO Bio), a clinical stage biotechnology company advancing the development of innovative therapies for cancer, today announced that IASO Bio will give an oral presentation with title 'Clinical Responses and Pharmacokinetics of fully human BCMA Targeting CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma' (abstract # 440) at 17th International Myeloma Workshop in Boston, MA. on Sept 12-15.
Nanjing, China., June 1, 2019-IASO Biotherapeutics(IASO Bio), a clinical stage biotechnology company advancing the development of innovative therapies for cancer, today announced that IASO Bio will give an oral presentation with title 'Efficacy and Safety of Fully Human BCMA Targeting CAR T Cell Therapy in Relapsed Refractory Multiple Myeloma' (abstract # S827, publication # 929) at 24th Congress of the European Hematological Society in Amsterdam, Netherlands on June 13-16.
Nanjing, China., April 09, 2019-IASO Biotherapeutics(IASO Bio), a clinical stage biotechnology company advancing the development of innovative therapies for cancer, today announced that IASO Bio will present clinical results (Abstract#8013) at American Society of Clinical Oncology Annual Meeting 2019 in Chicago Illionis on May 31-June 4.
Nanjing, China., April 09, 2019-IASO Biotherapeutics(IASO Bio), a clinical stage biotechnology company advancing the development of innovative therapies for cancer, today announced that IASO Bio will give an oral presentation with the title 'Fully Human BCMA targeted chimeric Antigen Receptor T Cells for Relapse/Refractory Multiple Myeloma' at Global Summit on Hematologic Malignancies in Urayasu, Japan on April 20-21.